Clinical Trials Directory

Trials / Completed

CompletedNCT01896388

Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Chiba University · Academic / Other
Sex
All
Age
13 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Accumulating evidence suggests a key role of the N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of post-traumatic stress disorder (PTSD). Recent studies suggest that the NMDA receptor antagonist ifenprodil tartrate may be a potential therapeutic drug for PTSD. The purpose of this study is to confirm whether ifenprodil tartrate is effective in the treatment of adolescents PTSD patients. If ifenprodil tartrate is effective in these patients, this study contributes to the development of novel therapeutic drugs for PTSD.

Conditions

Interventions

TypeNameDescription
DRUGIfenprodil Tartrate
DRUGPlacebo

Timeline

Start date
2014-01-21
Primary completion
2019-03-01
Completion
2019-03-01
First posted
2013-07-11
Last updated
2019-03-19

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT01896388. Inclusion in this directory is not an endorsement.